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Systemic lupus erythematosus (SLE) is a multi-
genic  systemic  autoimmune  disease  with  an 
immune complex–associated pathology that is 
prevalent among females of childbearing age.   
A hallmark of SLE is the appearance of serum 
antinuclear antibodies (ANAs) that appear to 
be  products  of  T  cell–dependent  immunity, 
manifested  by  high-avidity  binding,  somatic 
mutations,  and  derivation  from  B  cells  that 
have  undergone  substantial  clonal  expansion 
(Shlomchik et al., 1987a, 1990; Tan, 1989). 
SLE-associated antibodies are frequently, but 
not exclusively, directed against histones, double- 
stranded DNA (dsDNA), histone–DNA com-
plexes, and various ribonuclear proteins.
Considerable progress in dissecting SLE eti-
ology and pathogenesis has come largely from 
mouse models with a genetic predisposition for 
spontaneous SLE-like disease (Theofilopoulos 
and Dixon, 1985). These models have been   
especially useful in identifying genetic contri-
butions  to  specific  disease  manifestations  and 
the role played by toll-like receptors (TLRs) in 
targeting the autoimmune response to specific 
TLR agonists (Fairhurst et al., 2006; Shlomchik, 
2008). Spontaneous SLE-like disease in F1 hybrid 
mice  between  the  NZB  strain  and  several   
others bears striking resemblance to human SLE 
with respect to manifestations, genetics, and fe-
male gender bias. Genetic backcross studies in-
volving NZB mice have identified a gene-rich 
interval at the distal end of the NZB chromo-
some 1 that is strongly associated with sponta-
neous autoantibody development (Vyse et al., 
1997). This region is syntenic with a region of 
distal  chromosome  1  associated  with  human 
SLE (Tsao et al., 1997).
A complementary body of work investigat-
ing immunological self-tolerance has identified 
several mechanisms of tolerance that are poten-
tially breached in systemic autoimmunity. With 
respect to the B cell, these mechanisms involve 
anergy, receptor editing, clonal deletion, and   
a less well defined preplasma cell checkpoint 
(Goodnow et al., 2005; Culton et al., 2006; 
Nemazee, 2006). Studies of self-tolerance in   
B cells have relied heavily on mice carrying Ig 
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Systemic lupus erythematosus (SLE) is characterized by high-avidity IgG antinuclear anti-
bodies (ANAs) that are almost certainly products of T cell–dependent immune responses. 
Whether critical amino acids in the third complementarity-determining region (CDR3)  
of the ANA originate from V(D)J recombination or somatic hypermutation (SHM) is not 
known. We studied a mouse model of SLE in which all somatic mutations within ANA V 
regions, including those in CDR3, could be unequivocally identified. Mutation reversion 
analyses revealed that ANA arose predominantly from nonautoreactive B cells that diversi-
fied immunoglobulin genes via SHM. The resolution afforded by this model allowed us  
to demonstrate that one ANA clone was generated by SHM after a VH gene replacement 
event. Mutations producing arginine substitutions were frequent and arose largely (66%) 
from base changes in just two codons: AGC and AGT. These codons are abundant in the 
repertoires of mouse and human V genes. Our findings reveal the predominant role of SHM 
in the development of ANA and underscore the importance of self-tolerance checkpoints  
at the postmutational stage of B cell differentiation.
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HCDR3 is especially important because of its pivotal role in 
antigen binding, particularly with regard to nuclear antigens 
(Krishnan et al., 1996; Xu and Davis, 2000; Li et al., 2000; 
Guth et al., 2003). The HCDR3 caveat was common to all 
preceding studies and likely contributed to mixed interpreta-
tions regarding the role of SHM in the origin of ANA (Radic 
et al., 1989, 1993; Siminovitch et al., 1989; Xu and Davis, 
2000; Wellmann et al., 2005; Mietzner et al., 2008).
In this study, we used a model of spontaneous autoim-
munity in which all somatic mutations in V region genes of 
ANA-producing hybridomas could be unequivocally identi-
fied for reversion analyses. We found frequent unambiguous 
cases in which high-avidity autoimmune B cells were created 
from nonautoreactive precursors by SHM.
RESULTS
An SLE model for optimal identification of somatic mutations
Our objective was to determine whether B cells producing 
ANAs in SLE-like disease were derived from precursors that 
emerge in the bone marrow with an autoreactive BCR or from 
somatic mutants generated in the periphery. To this end, we 
generated a mouse in which all somatic mutations in monoclo-
nal autoreactive antibodies could be unequivocally identified, 
even in HCDR3. This was accomplished by breeding two 
copies of a targeted null Tdt allele into an autoimmune-prone 
C57BL/6.NZB-Nba2 mouse (B6.Nba2; Gilfillan et al., 1993). 
The Nba2 interval spans 20 centimorgans of DNA from   
distal chromosome 1 of the NZB strain and confers upon aged   
mice a spontaneous autoimmunity with many of the classical 
hallmarks of SLE, including ANAs and a female gender bias   
(Rozzo et al., 2001). Notably, the chromosome 1–distal Nba2 
interval is syntenic with a distal region of human chromosome 1   
that is genetically associated with SLE (Tsao et al., 1997). As 
such, the Nba2 strain is considered an excellent model of spon-
taneous ANA development in human SLE. In Tdt-null mice, 
diversity at the borders of assembling gene segments is still   
created as a result of gain or loss of nucleotides, but the gains, 
referred to as P elements, occur through a templated process   
after the opening of sealed hairpins at the ends of coding   
segments (Lafaille et al., 1989). Prior studies established the   
transgenes that encode autoantibodies to artificial or natural 
self-antigens. In these models, self-tolerance is remarkably   
efficient, and autoantibody-encoding transgenes have, at most,   
a modest effect on development of ANAs (Brard et al., 1999; 
Mandik-Nayak et al., 1999; Yachimovich-Cohen et al., 
2003; Steeves and Marion, 2004; Chen et al., 2006). When 
such transgenes are bred into autoimmune-prone strains, the 
autoreactive B cells that emerge are frequently oligoclonal 
and express edited receptors generated by endogenous Ig V 
gene rearrangements. Because it changes the unique identity 
of a B cell, receptor editing often obscures interpretations   
regarding the stages in B cell development when breaches   
in self-tolerance occur. Without this information, knowledge 
obtained from genetic mapping analyses, gene knockout stud-
ies, and other approaches cannot be fully interpreted in the 
context of disease etiology.
Many self-tolerance studies have focused on B cell devel-
opmental stages that precede immune activation, with the   
implicit assumption that autoreactive antecedents to disease-
associated autoimmune B cells are generated in the bone mar-
row immediately after Ig gene recombination. Autoreactive 
cells generated in this manner would have to escape every 
self-tolerance checkpoint to participate in systemic autoim-
munity (Goodnow et al., 2005). Alternatively, autoimmune   
B cells in SLE may be created by somatic hypermutation (SHM) 
in mature activated B cells responding to antigens in the   
periphery. Autoreactive B cells generated via this mutation-
founder scenario would have to traverse fewer tolerance 
checkpoints before participating in the autoimmune process. 
To distinguish between these alternatives, somatic mutations 
within V region genes of autoimmune B cells must be identi-
fied and reverted to germline sequence so that their contribu-
tion to the specificity and affinity of the autoreactive B cell 
receptor (BCR) can be evaluated. Efforts to interpret results 
of such analyses have been confounded by cell sampling issues, 
uncertainty over whether a cell expresses one or multiple   
receptors, and difficulties in identifying somatic mutations. 
Defining mutations is problematic because of V gene poly-
morphisms and the presence of untemplated nucleotides in 
the heavy chain third complementarity-determining region 
(CDR3 [HCDR3]) that are added by terminal deoxynucleo-
tidyl transferase (Tdt) during Ig gene recombination (Lafaille 
et al., 1989; Gilfillan et al., 1993). Yet defining mutations in 
Figure 1.  Chromatin-binding IgG anti-
bodies in B6.Nba2 Tdt/Igh+/Igk+/ 
mice. (A) Serum titers of IgG anti-chromatin 
antibodies from B6.Nba2 Tdt/Igh+/Igk+/ 
mice (8–10 mo old). Red line, representative 
serum from a nonautoimmune C57BL/6 
mouse. Standard errors are shown. (B) Chro-
matin binding assay with purified monoclonal 
antibodies generated from a spontaneously 
autoimmune B6.Nba2 Tdt/Igh+/Igk+/ 
mouse (female, 12 mo old). A prototypical 
ANA, 3H9/V4, is shown in red. Bound anti-
bodies were detected in a solid-phase euro-
pium (Eu3+)-based fluoroimmunometric assay 
(as counts per second). The figure shows one 
of two experiments with similar results.JEM VOL. 207, September 27, 2010 
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glomeruli of kidneys, as assessed by immunofluo-
rescence (unpublished data). A screen of hybridoma 
supernatants  for  IgG  antibodies  directed  against 
chromatin in a solid-phase europium-based immu-
noassay indicated that 5.7% (103/1,800) of them 
were positive. Representative results of a chromatin-
binding assay using highly purified antibodies from 
several recloned hybridomas are shown in Fig. 1 B. 
The binding avidity of many of these antibodies   
was similar to, and sometimes exceeded, that of   
the prototypical ANA 3H9/V4, which has served 
as a basis for numerous Ig transgene studies of toler-
ance and autoimmunity (Shlomchik et al., 1987a).
Heavy and light chain V region genes were se-
quenced for 30 of the hybridomas using a reverse transcriptase 
PCR procedure. The sequences were queried against entries 
in several databases, most notably the National Center for Bio-
technology Information C57BL/6 genome Build 36.0, to 
identify corresponding germline V gene segments used by 
each hybridoma. Unambiguous matches for VH, DH, JH, and 
Jk gene segments were found in every case and permitted   
somatic  mutations  to  be  identified  clearly  (Supplemental 
data). In a few cases, the heterozygous deficiency at the Igh 
locus also aided in the identification of mutations located at 
the gene segment boundaries. For example, we were able to 
infer that a thymidine nucleotide in the VH/D boundary in 
hybridomas J6.1 and J5.5 (lineage 4; Fig. 2) was added in a 
templated  manner  (P  element)  during  V  gene  segment 
assembly. Had it been inserted instead via SHM, the preced-
ing sequence would have been shifted out of the proper 
translational reading frame by 1 base and unable to encode a 
BCR, which is required for B cell survival.
V region gene sequences revealed that the 30 hybridomas 
represented 12 antecedent B cell clones. Seven clones were 
represented by one hybridoma each. Four clones were repre-
sented by two hybridomas each, and one large clone was 
represented by 15 hybridomas (Fig. 3). This indicated that 
half of the chromatin-reactive hybridomas that were sampled 
represented one large clone. Large lineages of autoimmune   
B cells in spontaneous SLE are common, as they have been 
seen in several other studies (Shan et al., 1994; Colombo   
et al., 2000; Zhang et al., 2001).
Structural evidence that autoreactivity was generated via SHM
Several key observations emerged from the sequence analyses 
to  support  the  idea  that  the  chromatin  reactivity  of  these   
antibodies was generated by SHM. First, every antibody was 
feasibility of this approach by demonstrating ANA in Tdt-
  deficient autoimmune mice (Conde et al., 1998; Molano   
et al., 2003).
In the absence of Tdt, somatic mutations in HCDR3 of 
ANAs can be clearly defined. It is equally important that   
somatic mutations in VH, DH, JH, and JL gene segments used 
by such antibodies can also be unambiguously identified be-
cause the genomic sequence of the C57BL/6 strain is known. 
Heterozygous deficiencies in the Ig heavy chain (Igh) and 
kappa light chain (Igk) loci were also introduced because   
B cells may express both kappa and heavy chain alleles as a 
result of receptor editing or failed allelic exclusion (Chen   
et al., 1993; Gu et al., 1993). The heterozygous deficiencies 
limited expression to one heavy chain allele and made it pos-
sible to determine whether an autoreactive B cell hybridoma 
was expressing two light chains ( + ; Giachino et al., 1995; 
Li et al., 2002; Rezanka et al., 2005). The heterozygous Igh 
deficiency also assisted in distinguishing P-element addi-
tions from somatic mutations at the boundaries of the gene   
segments encoding HCDR3. As such, the genetic makeup   
of the B6.Nba2 Tdt/Igh+/Igk+/ mouse allowed us to 
determine and reconstruct the original unmutated sequences 
of spontaneously arising ANAs before the advent of SHM.
Anti-chromatin antibodies  
in B6.Nba2 Tdt/Igh+/Igk+/ mice
As is typical of the B6.Nba2 strain, a majority of aged female 
B6.Nba2 Tdt/Igh+/Igk+/ mice developed high titers of 
serum anti-chromatin antibodies (Fig. 1 A). In most animals 
examined (6/8), these antibodies had already appeared by 5 mo 
of age. From one such spontaneously diseased mouse, we   
generated B cell hybridomas. In addition to anti-chromatin 
antibodies, this animal had substantial deposits of IgG in 
Figure 2.  HCDR3 sequences for clones subjected to  
mutation-reversion analysis. Germline-encoded DH sequences 
are shown above and germline-encoded VH and JH sequences 
are shown below hybridoma (shaded) sequences. Somatic 
mutations are underlined. The blue lowercase t in J6.1 is a 
templated nucleotide (P element) added during VH(D)JH recom-
bination. In lineage #4, somatic mutations that eliminated Arg 
codons are explicitly indicated for both members.2228 Origins of antinuclear B cells | Guo et al.
draw this conclusion with confidence. However, although 
HCDR3 arginines are often associated with affinity for   
nucleic acids, this is not always the case (Rahman et al., 
2001). In HCDR3 of lineage #4, a pair of Arg codons sus-
tained nonsynonymous somatic mutations. In hybridoma 
J5.5, a VH Arg codon near the boundary with the D gene 
segment was mutated to a Thr codon (Fig. 2). In the other 
hybridoma of lineage #4 (J6.1), a mutation at the beginning 
of the D gene segment produced an Arg to Ser codon con-
version (Fig. 2).
Finally, few of the clones showed signs of light chain   
receptor editing (Gay et al., 1993; Tiegs et al., 1993). None 
of the antibodies expressed a lambda light chain, and only 3 
of the 12 clones used distal Jk5 or Jk4 gene segments (Table I). 
This is approximately the frequency expected for clones   
attempting to negotiate a productive rearrangement. Collec-
tively, these structural observations were consistent with   
the idea that many of the chromatin-reactive B cells were 
derived from nonautoreactive B cells in secondary lymphoid 
tissues via the process of SHM.
A large autoreactive lineage derived  
from a nonautoreactive B cell
To test the mutation-founder idea conclusively, we reverted 
the 15 nonsynonymous mutations shared by all members   
of the large lineage #1 to regenerate codons expressed by 
the original B cell as it emerged in the bone marrow before 
SHM.  These  included  the  HCDR3  somatic  mutations,   
as illustrated in Fig. 2 (top sequence). The primers used   
to construct the template for reversion mutagenesis were 
located distally with respect to the 
variable gene coding sequences to ac-
curately recreate all features of the un-
mutated (and mutated) variable genes, 
including the leader sequences.  This 
was done because mutations in leader 
sequences can affect antibody bind-
ing (Ping et al., 1993). The reverted 
constructs  were  transfected  in  the 
context  of  an  IgG2b  genomic  ex-
pression  vector  into  SP2/0  cells  to 
produce antibody, which was affinity 
encoded by somatically mutated V region genes, carrying 
from 2 to 24 aa replacements (Table I). Second, each multi-
member  lineage  was  defined  by  shared  somatic  mutations 
producing amino acid replacements among all clone members 
(Fig. 3). This is a prediction of the mutation-founder scenario. 
In the large lineage #1, for example, all members shared 17 
somatic mutations, 15 of which produced amino acid replace-
ments. A strong selection event apparently drove the prolifer-
ation of a single mutated B cell relative to its siblings at or near 
the time it had acquired the 17th somatic mutation. At this 
point, we infer that the cell was strongly autoreactive because 
an engineered antibody containing only these shared muta-
tions bound strongly to chromatin (unpublished data). Third, 
11 of 12 clones carried somatic mutations producing arginine 
(Arg) residues, and in four of the five multimember lineages, 
there was at least one mutation producing a shared Arg re-
placement among clone members (Table I and Supplemental 
data). Arg residues are often critical for antinuclear specificities 
(Radic and Weigert, 1994; Kalsi et al., 1996; Krishnan et al., 
1996; Jang et al., 1998; Li et al., 2000; Rahman et al., 2001; 
Tanner et al., 2001; Guth et al., 2003; Haley et al., 2004). 
Studies with DNA-binding proteins have shown that their 
flexible side chains can interact via hydrogen bonds with bases 
in the major and minor grooves of DNA or form salt bridges 
and  hydrogen  bonds  with  the  phosphodiester  backbone   
(Steitz, 1990; Luscombe et al., 2001). One of the two shared 
arginine mutations in lineage #1 occurred in HCDR3 at the 
boundary of the DFL16.1 gene segment and the JH1 gene seg-
ment (Fig. 2). Had this clone been derived from a mouse with 
a functional gene for Tdt, we would not have been able to 
Figure 3.  Dendrograms of multimember 
lineages. Numbers of somatic mutations are 
indicated along each branch, where r denotes 
an amino acid replacement and red indicates 
a mutation shared by all members of the lin-
eage. The length of a branch is proportional to 
the number of somatic mutations. Clones 
from the first animal subjected to reversion 
are colored green, and those from a second 
autoimmune mouse are in yellow. Four of 
seven clones from the first animal that were 
represented by single hybridomas and sub-
jected to reversion are shown.JEM VOL. 207, September 27, 2010 
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Table I.  Summary of hybridoma V region genes
Hybridoma V germline genes and shared 
mutations; shared replacementsa
Mutations: total; 
replacements
 VH germline genes, isotype, and shared 
mutations; shared replacements
 Mutations: total; 
replacements
Unanimously shared 
Arg mutations
Lineage #1 (mouse 1)
J1.1 V CR-1/J2 unanimously shared 
mutation10; 8r
15; 9r VH7183.9.15/ DFL16.1/ JH1 2b 
unanimously shared mutations 7r
11; 10r 0 V; 2 VH
J1.4 13; 9r 13; 11r 0 V; 2 VH
J2.6 14; 9r 9; 8r 0 V; 2 VH
J2.7 14; 10r 10; 8r 0 V; 2 VH
J3.1 12; 8r 8; 7r 0 V; 2 VH
J3.4 10; 8r 13; 9r 0 V; 2 VH
J3.8 11; 9r 11; 8r 0 V; 2 VH
J4.2 10; 8r 11; 9r 0 V; 2 VH
J5.8 14; 9r 9; 8r 0 V; 2 VH
K5.14 14; 9r 9; 8r 0 V; 2 VH
J7.18 14; 8r 13; 9r 0 V; 2 VH
J9.7 13; 8r 12; 10r 0 V; 2 VH
J10.7 10; 8r 13; 9r 0 V; 2 VH
J10.13 11; 8r 11; 7r 0 V; 2 VH
K6.23 13; 9r 7; 7r 0 V; 2 VH
Lineage #2 (mouse 1)
J2.8b V ai4/ J1 unanimously shared 
mutations 1r
2; 2r VH3609.12.174/ DSP2.2/JH1 2c/2b 
unanimously shared mutations 2; 1r
2; 1r 0 V; 0 VH
J7.13b 1; 1r 5; 2r 0 V; 0 VH
Lineage #3 (mouse 1)
J3.7 V CR-1/J1 unanimously shared 
mutations 3; 2r
19; 12r VHJ558.59.155/DSP2.2/JH3 1 
unanimously shared mutations 3; 2r
21; 12r 0 V; 1 VHc
K6.18 11; 7r 11; 9r 0 V; 1 VH
Lineage #4 (mouse 1)
J5.5 V 23-43 /J5 unanimously shared 
mutations 1r
5; 4r VHQ52.2.4/DST4/ JH2 2c Unanimously 
shared mutations 6; 3r
10; 5r 1 V; 0 VH
J6.1 4; 3r 9; 6r 1 V; 0 VH
Lineage #5 (mouse 1)
J3.9 V ai4/ J2 unanimously shared 
mutations 6r
9; 8r VHJ558.26.116/DQ52/JH3 1 
unanimously shared mutations 5r
8; 6r 3 V; 1 VH
J3.10 7; 7r 15; 9r 3 V; 1 VH
Single clones (mouse 1)
J3.11 V ai4/ J5 11; 7r VHJ558.26.116/DSP2.5/ JH2 2c 25; 15r 1 V; 0 VH
J3.12 V aa4/ J1 2; 0r VH7183.20.37/DSP2.x/JH4 2c 13; 11r 0 V; 1 VH
J6.2 V 23-39/J2 17; 9r VHJ558.79.184/DST4/JH4 2c 16; 9r 1 V; 1 VHd
J9.11 V 23-45/J4 1; 1r VHJ558.75.177/DSP2x/JH1 2c 1; 1r 1 V; 0 VH
J10.12 V19-25/J1 7; 5r VH3609.12.174/ DSP2.x/JH1 2c 4; 4r 0 V; 1 VH
J10.24 V ai4/J2 8; 4r VHJ558.26.116/DSP2.2/JH2 1 3; 3r 1 V; 0 VH
K6.16 V 23-43/J2 10; 6r VHJ588.2.88/ DFL16.1/JH2 1 18; 11r 1 V; 1 VH
Lineage #6 (mouse 2)
N3.18 Ai4/Jk2 7; 4r VHJ558.26.116/DSP2.5/JH4 2c 15;13r 1 V; 0 VH
N12.6 Unanimously shared mutations 3; 1r 13; 6r Unanimously shared mutations 14; 12r 15;13r 1 V; 0 VH
Single clones (mouse 2)
Q10.4 23-43/Jk5 4; 3r VHJ558.26.116/DFL16.1/JH1 2c 2; 1r 1 V; 0 VH
Empty cells in the second and fourth columns indicate the same information as the cell above.
aAmino acid replacements due to somatic mutation.
bJ2.8 is 2c; J7.13 is 2b.
cMembers of this clone share an Arg replacement in VH CDR1 but as a result of different base substitutions (mutations).
dArg codon may be the result of either a somatic mutation in CDR3 or a P-element addition.2230 Origins of antinuclear B cells | Guo et al.
chosen because no Arg replacement mutations were shared by 
its two members. Lineage #4 was selected because its two mem-
bers used a Jk5 gene segment, suggesting that the clone may 
have exhausted options for receptor editing in attempts to re-
place an autoreactive BCR. A third clone (J9.11) was chosen 
because its antibody V genes contained the fewest number   
of nonsynonymous somatic mutations (only 2) among the   
30 clones that were examined. In addition, it also used a distal 
Jk4 gene segment. All antibodies were purified as described for 
lineage #1 and tested in various binding assays. Despite their 
structural features, each of these clones sustained dramatic 
losses  in  autoreactivity  activity  upon  mutation  reversion, 
completely in two cases and 50-fold in the third (Figs. 4 
and 5). In addition, neither the revertants nor the original 
mutant mAb bound to cardiolipin detectably (Fig. S1). As 
with lineage #1, the transfection and expression methods 
were validated by recreating and expressing the three mutants 
in the context of the IgG2b expression vector. In each case, 
autoreactivity was preserved.
As a final test, we reverted the somatic mutations in six 
additional ANA-producing clones. Two of these were from 
a second 8-mo-old autoimmune female mouse with serum 
anti-chromatin IgG, although of a lower titer than previous 
mouse. Only 0.5% of the hybridomas (4/832) from this 
animal was initially scored positive for IgG anti-chromatin. 
One of these clones was represented by two hybridomas   
(Fig. 3). The other 4 clones were from the original set of 12 
derived from the first animal. In every case, the germline re-
vertants lost all detectable autoreactivity as assessed in solid-
phase binding assays against chromatin, in immunofluorescence 
assays against fixed HEp-2 cells, and in immunofluorescence as-
says against whole frozen sections of neonatal mice (Figs. S1–4). 
It  is  clear  from  these  analyses  that 
SHM  frequently  created  antinuclear 
clones from nonautoreactive precur-
sors;  in  9  of  10  clones,  SHM  was   
responsible for all detectable autoreac-
tivity and in the 10th clone for almost 
all of it.
purified and treated with DNase and 1 M NaCl to remove 
potential contaminating nuclear antigens as previously de-
scribed (Guth et al., 2003). This was done because unpuri-
fied  ANAs  from  culture  supernatants  can  display  altered 
binding specificity and avidity profiles as a result of contam-
inating nuclear antigens that may form a bridge between the 
antibody and an intended target antigen in immunoassays.
Binding  immunoassays  revealed  that  the  revertant  Ab   
of lineage #1 lost all measurable affinity for chromatin, as 
well as for various nuclear antigen subspecificities (Fig. 4). 
The revertant also failed to demonstrate detectable antinu-
clear activity against fixed HEp-2 cells by immunofluores-
cence, even when used at a substantially higher concentration 
than that of the original mutant antibody (Fig. 5 A). Finally, 
the revertant failed to bind detectably any tissue antigen in 
frozen sections of whole neonatal mice, as assessed by immu-
nofluorescence (Fig. 5 B). To validate our IgG2b transfection 
vector and procedure, we also reconstructed the original mu-
tant antibody and expressed it in SP2/0 cells. The mutant   
Ab generated in this way retained its original activity, as   
expected (unpublished data). On the basis of these results,   
we conclude that the largest chromatin-reactive clone was 
derived from a normal B cell whose antinuclear specificity 
was created by SHM.
Other autoreactive clones created by SHM
To determine whether mutation-generated autoreactivity in 
the large clone was the exception or the rule, we interrogated 
additional independent clones by reversion analysis. As a rig-
orous test, we initially chose three clones with characteristics 
suggesting that they might have emerged with antinuclear 
BCR  directly  from  the  bone  marrow.  Lineage  #2  was   
Figure 4.  Chromatin binding assays for 
monoclonal antibodies and engineered 
revertants lacking somatic mutations. 
Standard errors are shown. R and red font 
color denote germline revertants. Two of the 
original monoclonal antibodies (J3.4 and 
J9.11) demonstrated binding activity against 
several chromatin components as shown in 
B–D. All antibodies were purified by a strin-
gent affinity method designed to remove 
potentially contaminating nuclear antigens 
(Guth et al., 2003). A prototypical ANA,  
3H9/V4, is shown in blue in A. Bound anti-
bodies were detected in a solid-phase euro-
pium (Eu3+)-based fluoroimmunometric  
assay (as counts per second). One of three 
experiments with similar results is shown.JEM VOL. 207, September 27, 2010 
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VH gene (VH12.1.78) that contained the GAGACAGA se-
quence precisely at its 3 end. This VH gene also contained 
a cryptic heptamer recombination signal sequence located 
3 bases immediately 5 of GAGACAGA. When the trans-
lational reading frame of VH12.1.78 was extended through 
the recombined VH/D junction, it terminated in two con-
secutive stop codons within the DFL16.1 gene segment 
(Fig. 6 B). These observations reveal that the Q10.4 ANA 
clone had traversed a circuitous pathway to autoimmunity. 
It had originally carried a nonproductive VH12.1.78/DFL16.1/
JH1 gene in which VH12.1.78 was subsequently replaced by 
VHJ558.26.116 to generate a productive heavy chain gene. 
After Vk gene rearrangement, it is possible that the original 
B cell was autoreactive and underwent receptor editing, as 
suggested by the use of Jk5. Alternatively, several Vk recom-
bination events terminating in a Vk-Jk5 exon may have been 
required to produce the first functional kappa gene. Either 
way,  subsequent  SHM  then  generated  the  autoreactive   
nuclear specificity in this cell. To our knowledge, this is   
the first demonstration of an endogenous VH gene replace-
ment that corrected a naturally occurring nonproductive 
V/D/J rearrangement.
The precursor to an ANA-producing clone generated  
by VH gene replacement
The absence of Tdt in these autoimmune mice enabled us 
to define the origins of nucleotides at junctional boundar-
ies of assembled V, D, and J gene segments encoding the 
ANA in our panel. Clone Q10.4 was unusual because it 
had 8 bases at the VH/D boundary that were derived nei-
ther from the corresponding VHJ558.26.116 and DFL16.1 
gene segments nor from a P-element addition (Fig. 6 A). 
To determine if this short sequence was a residual footprint 
left by a VH gene replacement event (Kleinfield et al., 1986; 
Reth et al., 1986; Zhang, 2007), we searched 1.2 mega-
bases  of  B6  genomic  DNA  located  downstream  of  the 
VHJ558.26.116  gene  for  this  sequence  (GAGACAGA). 
This region of DNA included all VH genes located between 
VHJ885.26.116 and the D gene segment cluster, any one   
of which was a potential candidate for replacement by a 
secondary rearrangement involving VHJ558.26.116. The 
GAGACAGA sequence was found 60 times. For each of 
the 60 hits, we extracted the preceding 300 bases and per-
formed an Ig BLAST search to determine if they encoded 
a VH gene in any reading frame. This analysis produced one 
Figure 5.  Immunofluorescence staining of HEp-2 cells and whole frozen sections of neonatal mouse with monoclonal antibodies and  
engineered revertants without somatic mutations. (A) Stains of fixed HEp-2 cells. R and red font color denote revertant. Note higher concentrations 
used for revertant antibodies. 3H9/V4 and 36–71 served as positive and negative controls, respectively. The experiment was performed three times. Bar, 
100 µm. (B) Stains of whole frozen sections of neonatal mice. Mutant antibody J6.1 served as positive control. Experimental section was stained with a 
mixture of revertant antibodies (RJ3.4, RJ9.11, and RJ6.1), each at a concentration equivalent to that of the positive control J6.1 mAb. Bound positive  
antibodies were detected with an FITC-coupled sheep anti–mouse IgG (-chain specific). Sections were counterstained with DAPI (blue) to highlight  
organs (In, intestine; Li, liver; K, kidney; Lu, lung; H, heart; Br, brain; E, eye). One of two experiments with similar results is shown. Bar, 3 mm.2232 Origins of antinuclear B cells | Guo et al.
frequently in VH genes and 1.6× more frequently in Vk genes 
than expected on the basis of either random codon use or 
actual codon use by other mouse genes. AGT use by mouse   
V genes was even higher (Table III). Finally, similar results 
for both codons were seen when all human VH and Vk and 
V genes in the BLAST Ig database were analyzed. The re-
sults were nearly the same when only one allele (listed first 
in the database) for each of the human V genes was analyzed. 
Collectively, these observations support the idea that SHM 
frequently creates nuclear-reactive B cell clones from normal 
B cell clones and that this occurs by mutations that convert 
AGC and AGT serine codons to arginine codons.
DISCUSSION
The results of this study provide conclusive evidence that 
SHM generates spontaneous autoreactive B cells that partici-
pate in systemic autoimmunity. By generating ANA-producing 
hybridomas from mice with a homozygous genetic defi-
ciency  in  Tdt  and  heterozygous  deficiencies  at  the  Igh   
and Igk loci, we were able to unequivocally identify all of 
the  somatic  mutations  in  V  region  genes  of  spontaneous 
ANA-producing B cells and to test them functionally in re-
version analyses. The requirement of somatic mutations for 
antinuclear activity was absolute in 9 of 10 clones analyzed 
and included a large lineage comprising approximately half 
of the sampled B cells. A predominant fraction of mutations 
producing Arg codons occurred at AGC and AGT serine 
codons, which are abundant in V genes and able to mutate 
to an Arg codon by 3 alternative base changes. AGC is also 
the  most  intrinsically  mutable  codon  substrate  for  SHM. 
Considering the importance of Arg residues in antinuclear 
activity, these findings collectively support the idea that SHM 
routinely generates ANA-specific B cells during T cell–
  dependent immunity.
We are confident that all functionally relevant binding 
was lost in nine of the clones examined because multivalent 
immunoassays are so sensitive that they can reveal binding 
interactions that are below the threshold required for im-
mune recruitment. In the arsonate (Ars) model, for example, 
a canonical antibody can be readily detected in immunoassays 
with protein conjugates of sulfanilic acid (Sulf), even though 
immunization with Sulf-carrier protein does not recruit cells 
producing this antibody (Fish et al., 1989). Clone J7.13 is the 
one exception that retained a small measure of antinuclear 
A propensity for arginine mutations at specific serine codons
Many studies have indicated the important role of Arg resi-
dues in antinuclear activity (Radic and Weigert, 1994; Kalsi 
et al., 1996; Krishnan et al., 1996; Jang et al., 1998; Li et al., 
2000; Rahman et al., 2001; Tanner et al., 2001; Guth et al., 
2003; Haley et al., 2004). In agreement with this, when   
the single Arg replacement mutation in the J9.11 clone   
(Vk CDR1) was reverted to a germline serine codon, there was 
nearly a complete loss of anti-chromatin activity in the resul-
tant antibody (Fig. S5). Arg mutations can also impart posi-
tive charges to antibodies, and there are studies reporting that 
cationic ANAs are prone to deposit in the kidney and induce 
pathology (Ebling and Hahn, 1980; Dang and Harbeck, 
1984). Although several of our antibody V regions with Arg 
mutations  had  relatively  high  calculated  isoelectric  points   
(pI = 9.1–9.4), we did not see evidence of pathology when 
they were injected (as hybridomas) into irradiated BALB/c 
mice (unpublished data).
A close inspection of all Arg mutations within our panel 
of hybridomas revealed that a majority of them occurred at 
AGC and AGT serine codons. 40% of independent Arg mu-
tations in VH and Vk genes expressed by our hybridoma panel 
were at AGC (Table II). This is likely a result of the fact that 
AGC is the most intrinsically favored triplet target of SHM 
and because AGC can mutate to an arginine codon by any   
1 of 3 different single base changes (Smith et al., 1996). In 
addition, the AGC codon is well represented in Ig V genes of 
our hybridoma panel; it is present in the Vk and VH genes at 
approximately two and three times the frequency expected 
for random codon use, respectively. Although AGT is not a 
prefered target of SHM, it is also well represented in the VH 
and Vk genes of our panel, at 2.2 and 6.6× the frequency ex-
pected for random codon use (Table II). Moreover, the com-
bined frequencies of AGC and AGT in CDR1 and CDR2 
are even higher, at 4.3 (VH) and 7.1 (Vk)× that expected. This 
is reminiscent of an observation reported by Radic and Weigert 
(1994) that among the six serine codons, AGC and AGT were 
overrepresented in CDR of a sample of ANA V genes. Collec-
tively, mutations at AGC and AGT accounted for 66% (20/30) 
of all Arg mutations in the V genes of our panel.
These  observations  prompted  us  to  analyze  codon 
use by all C57BL/6 Ig VH and Vk genes listed in the Ig   
Blast public database (http://www.ncbi.nlm.nih.gov/igblast/). 
This analysis revealed that AGC was used 1.9× more   
Figure 6.  Functional Igh gene for the Q10.4 
hybridoma created by VH replacement. (A) The 
Q10.4 VH/D/JH boundary sequence illustrating an  
8-base sequence remaining from the original 
VH12.1.78 rearrangement in red. (B) The original 
VH12.1.78 rearrangement showing the nonproductive 
translational reading frame ending in consecutive 
stop codons (red). The cryptic heptamer recombina-
tion signal sequence within VH12.1.78 is shown in 
blue. The 8-base sequence of VH12.1.78 that is  
destined to remain after replacement by 
VHJ558.26.116 is also shown in red.JEM VOL. 207, September 27, 2010 
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et al., 2008). Whether the conclusion of our study applies to 
autoantibodies in other autoimmune diseases is unknown.   
It is noteworthy, however, that in young children that prog-
ress to type I diabetes, the first anti-insulin antibodies detected 
in serum are high-avidity IgGs (Palmer et al., 1983; Yu et al., 
2000). This may be an indication that their insulin specifici-
ties are generated by SHM.
In testing the relevance of somatic mutations to the anti-
nuclear activity of a given antibody, we took the precaution 
of eliminating all of them. This was done because preserva-
tion or improvement of a germline-determined affinity might 
require several somatic mutations, whereas a subset of the 
same mutations might be destructive. One somatic mutation 
might be functionally destructive if acquired before, but ben-
eficial if acquired after, another mutation. The hybridoma 
sampling approach was also an important component of our ap-
proach. Many studies have demonstrated a strong concordance 
between serum antibodies and mAb produced by hybridomas 
sampled in physiological and disease settings (Reth et al., 
1978; Griffiths et al., 1984; Wysocki et al., 1986; Shlomchik 
et  al.,  1987b).  However,  the  relationship  between  serum 
ANA and receptors expressed by B cells bearing markers of 
memory  is  not  as  well  defined.  Cells  sorted  for  memory 
markers might include a tolerant category, as suggested by 
the high frequency of antinuclear BCR specificities observed 
in  such  cells  isolated  from  nonautoimmune  individuals   
(Tiller et al., 2007) and by the observation that in mouse 
models of immunity to foreign antigens, autoreactivity tends 
to be purged during memory B cell development (Notidis   
et al., 2002; Guay et al., 2004).
activity after reversion, raising the possibility that it escaped 
all tolerance checkpoints in B cell development. Alterna-
tively, the avidity of the germline antecedent of J7.13 for 
self-antigen may be physiologically irrelevant and insufficient 
to induce a tolerant phenotype. It is noteworthy that clone 
J7.13 used a Jk1 gene segment. This could reflect insufficient 
avidity for self-antigen to induce receptor editing or a defect 
in receptor editing in B6.Nba2 mice. Distinguishing between 
these can only be determined by generating mice that carry 
an unmutated version of this BCR and comparatively analyz-
ing the resultant B cells in B6 and B6.Nba2 mice.
Our approach avoided caveats that previously obscured 
complete identification of somatic mutations in disease-
  associated autoreactive B cells. Chief among these was the 
undefined nature of unmutated CDR3 sequences in anteced-
ents to autoimmune clones. This was resolved by an absence 
of Tdt in our mice. The high resolution imparted by a Tdt 
deficiency is underscored by the fact that it enabled us to de-
fine, for the first time, an endogenous VH gene replacement 
that corrected a naturally generated nonproductive V/D/J 
gene. The subset of prior studies that interpreted somatic 
mutations as being critical to ANA, particularly those involv-
ing human ANA, did not have the benefit of genetic abla-
tions to define the role of somatic mutations in CDR3 and   
of secondary rearrangements to autoreactivity. Nevertheless, 
these preceding studies framed an important issue and pro-
vided the first evidence that somatic mutations were required 
for the generation of disease-associated ANA (Radic et al., 
1989, 1993; Siminovitch et al., 1989; Xu and Davis, 2000; 
Wellmann et al., 2005; Lambrianides et al., 2007; Mietzner   
Table II.  Frequent Arg mutations at AGC and AGT codons in V genes
V genes Arg mutations at 
AGC
Arg mutations at  
AGT
AGC codons in V 
genesa
AGT codons in V 
genes
AGC+AGT CDR1 and 
CDR2
AGC+AGT FR1 and 
FR2
% % % % % %
VH 41.7 16.7 3.7 2.0 10.8 1.8
V 38.9 33.3 3.0 6.1 17.9 1.9
This table refers to anti-chromatin antibodies in this study.
aAGC and AGT codon usage among 52,926 mouse genomic codons is 1.6 and 0.92%, respectively (GenBank: http://www.kazusa.or.jp/codon/cgi-bin/showcodon 
.cgi?species=10092).
Table III.  Frequent use of AGC and AGT codons in antibody V genes
V genes AGC codon use AGT codon use
All mouse V genesa All human V genesb All mouse V genes All human V genes
% % % %
VH 3.1 3.4 1.67 2.2
V 2.6 3.9 5.5 4.7
V 2.4 3.4 2.4 2.4
This table shows V gene sequences taken directly from Ig BLAST (http://www.ncbi.nlm.nih.gov/igblast/). A majority of the Ig BLAST sequences were from the international 
ImMunoGeneTics information system (IMGT; http://www.imgt.org).
aAGC and AGT codon usage among 52,926 mouse genomic codons is 1.6 and 0.92%, respectively (GenBank: http://www.kazusa.or.jp/codon/cgi-bin/showcodon 
.cgi?species=10092).
bAGC and AGT codon usage among 40,662,582 human genomic codons is 1.95 and 1.21%, respectively (GenBank: http://www.kazusa.or.jp/codon/cgi-bin/showcodon 
.cgi?species=9606).2234 Origins of antinuclear B cells | Guo et al.
preimmune repertoire may ensure that it is populated with   
B cells that are most likely to generate successful progeny if   
recruited into an immune response. From this perspective,   
receptor editing and deletion of autoreactive B cells in the 
preimmune repertoire may be viewed as quality control mea-
sures that ultimately enhance immune responses. The exis-
tence of receptor editing as a potential salvage operation 
supports the idea that generating a functional B cell repertoire 
is a difficult or energetically expensive prospect, otherwise de-
letion should suffice. This idea is also supported by microse-
quence substrate preferences of the SHM mechanism, which 
has an intrinsic target bias to limit structural damage to the   
V region (Dörner et al., 1997; Kepler, 1997; Shapiro et al., 
2002). This quality control idea leads to the prediction that 
defects in receptor editing and deletion of autoreactive B cells 
in the preimmune repertoire would result in compromised 
humoral immunity.
MATERIALS AND METHODS
Mice. B6.Nba2 congenic mice were described previously and were provided 
by S. Rozzo and B. Kotzin (University of Colorado Health Sciences Center; 
Denver,  CO;  Rozzo  et  al.,  2001).  Tdt-deficient  mice  were  provided  by   
D. Mathis (Harvard University, Cambridge, MA; Gilfillan et al., 1993). Kappa 
gene-deficient mice were provided by D. Huszar (AstraZeneca R&D Boston, 
Waltham, MA; Chen et al., 1993) and heavy chain gene–deficient mice (Gu 
et al., 1993) were purchased from The Jackson Laboratory. All loci were previ-
ously bred onto a B6 genetic background and intercrossed to generate B6.Nba2 
Tdt/IgH+/Igk+/ mice in the Biological Resource Center at National 
Jewish Health. All animals were handled according to a protocol approved by 
the Institutional Animal Care and Use Committee of National Jewish Health. 
Genotyping was performed by PCR with primers shown in Table S1.
Hybridoma production. Hybridomas were generated from a 12-mo-old 
B6.Nba2 Tdt/IgH+/Igk+/ spontaneously autoimmune mouse using 
the SP2/0/ mIL-6 fusion partner (Harris et al., 1992). Hybridoma culture 
supernatants were tested for the production of IgG antibodies in a Eu+-
linked fluoroimmunoassay using a goat anti–mouse IgG H-chain–specific 
antibody (SouthernBiotech) as described in Antibody binding assays. Hybrid-
omas that scored positive were cloned by limiting dilution. Heavy chain   
isotypes of monoclonal antibodies were determined by ELISA using an   
isotyping kit (SouthernBiotech).
Sequencing hybridoma V region genes. Variable genes of the hybrid-
omas were cloned with RT-PCR and 5 rapid amplification of cDNA ends 
(RACE) using sets of constant region primers and anchor primers. Total 
RNA was isolated from the hybridomas with RNeasy (QIAGEN), and first-
strand cDNA was synthesized with Superscript III RT (Invitrogen) using an 
oligo (dT) primer. First-strand cDNA was purified using QIAquick (QIAGEN), 
and  a  poly  (dG)  tail  was  added  to  3  ends  with  Tdt  (Invitrogen)  at   
37°C for 20 min in the presence of 0.4 mM dGTP. First-round 5 RACE 
PCR was performed on 5 µl of tailed cDNA using high-fidelity Phusion 
DNA polymerase (Finnzymes) with anchor primer 1 and a heavy chain or 
light chain constant region outer primer (Table S1) under the following 
conditions: an initial incubation at 98°C for 1 min; then 18 cycles at 98°C 
for 30 s, 55°C for 30 s, and 72°C for 1 min; and a final incubation at 72°C 
for 10 min. Second-round PCR was performed on 1 µl of first-round PCR 
product with anchor primer 2 and a nested constant region heavy chain or 
light chain primer under the following conditions: an initial incubation at 
98°C for 1 min; then 20 cycles of 98°C for 30 s, 60°C for 30 s, and 72°C for 
1 min; and a final incubation at 72°C extension for 10 min. Heavy chain 
PCR products were extracted from 2% agarose gels and inserted into the 
pCR4-TOPO vector (Invitrogen). Light chain PCR products were purified 
The patterns and frequencies of somatic mutations in our 
clones indicated that autoimmune B cells were generated at 
both early and late stages after induction of SHM. For ex-
ample, some of the mutant antinuclear B cells carried few 
mutations, whereas members of the large lineage shared 17 so-
matic mutations, indicating strong selection at or near the time   
that the last shared mutation was acquired. SHM normally 
diversifies antibody genes during physiological responses to 
foreign  immunogen  within  the  microenvironment  of  the 
germinal center (GC). Therefore, the most straightforward 
interpretation of our results is that the mutant antinuclear   
B cells were generated de novo at this time (Apel and Berek, 
1990; Jacob et al., 1991). Although we favor this idea, it is 
conceivable that SHM and selection are not properly regu-
lated and occur elsewhere in B6.Nba2 mice. SHM outside of 
the GC has been reported for rheumatoid-factor B cells in 
one model of autoimmunity (William et al., 2002). Either 
way, our results support the counterintuitive conclusion that 
a developing B cell emerging from the bone marrow with a 
normal nonautoreactive BCR may be more dangerous than 
one arising with an autoreactive BCR.
In autoimmune-prone mice that express transgenic anti-
nuclear BCR, the autoimmune clones that ultimately arise in 
disease often express altered BCRs that are products of recep-
tor editing. One possible explanation is that upon receptor 
editing, the precursors either replaced one autoreactive BCR 
with another or were unable to dilute the autoreactive BCR 
by expressing a second benign heavy or light chain gene. Our 
findings suggest an alternative possibility. Editing may have 
been functionally successful, thus permitting the B cells to 
survive early self-tolerance checkpoints, become engaged in 
an immune response, and undergo SHM to become autore-
active. A mature B cell that gains autoreactivity during im-
munity has to escape fewer tolerance checkpoints than one 
that emerges in the bone marrow with an autoreactive BCR.
Several observations support the idea that SHM frequently 
creates autoreactive B cells during the GC reaction. The vary-
ing numbers of shared somatic mutations in our lineages indi-
cate that mutations creating antinuclear BCR can apparently 
be acquired at early or late time points after the commence-
ment of SHM. In addition, there appears to be a bias favoring 
somatic mutations that generate Arg codons because of an 
abundance of specific serine codons in antibody V genes that 
have an intrinsic bias to mutate to Arg codons or are pre-
ferred targets of SHM. Nevertheless, previous studies have 
demonstrated one or more tolerance checkpoints at, or after, 
the GC phase of B cell differentiation (Hande et al., 1998; 
Culton et al., 2006). This raises an intriguing question: if ANA-
specific B cells are frequently generated in the GC and must 
subsequently be censored, what is the major benefit of self-
tolerance checkpoints during development of the preimmune 
B cell repertoire?
One possibility to consider is that early censorship offers 
the  added  benefit  of  preventing  autoreactive  B  cells  from 
competing with normal B cells for physical and functional 
niches in the immune system. As such, central tolerance in the JEM VOL. 207, September 27, 2010 
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Immunofluorescence assays. mAbs were tested for autoreactivity against 
fixed HEp-2 cells (Bio-Rad Laboratories) and against frozen sections of a 
whole neonatal mouse adhered to ProbeOn Plus microscope slides (Thermo 
Fisher Scientific). Slides were incubated with mAb for 30 min, washed with 
PBS for 5 min, and incubated with FITC-labeled sheep anti–mouse IgG   
antibody (1/200; Sigma-Aldrich) for 30 min. For frozen sections, slides were 
covered with mounting medium containing DAPI (Vector Laboratories). 
Pictures were taken with an inverted microscope (Axiovert 200M; Carl 
Zeiss, Inc.) at 200× (HEp-2) or 100× (frozen sections) magnification. A mon-
tage of images taken of frozen sections was assembled using Slidebook 4.1 
software (Intelligent Imaging Innovations Inc.).
Online supplemental material. Fig. S1 shows an anti-cardiolipin binding 
assay performed with ANA and engineered revertants. Fig. S2 shows an anti-
chromatin binding assay with ANA and engineered revertants. Fig. S3 shows 
immunofluorescent staining of HEp-2 cells with six ANAs and engineered 
revertants not represented in Fig. 5 A. Fig. S4 shows immunofluorescent 
staining of whole frozen sections of a neonatal mouse with six revertants not 
analyzed in Fig. 5 B. Fig. S5 demonstrates that a single kappa Arg mutation 
is required for high-avidity binding by the J9.11 clone.Table S1 is a composi-
tion of all primers used for amplification and cloning throughout the project. 
Supplemental data shows the sequences of the mutated antibody V regions 
that were subjected to reversion analysis. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20092712/DC1.
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